This is also evident in the therapeutic approach of both diseases, where RA profits from TNF inhibition, while SLE is combatted by B cell-depleting agents, like belimumab, whereas anti-TNF treatment exacerbates or even induces SLE. The gene discussed is TNF; the disease is systemic lupus erythematosus.